Antonio Cuneo

Hematology Section, Azienda Ospedaliero-Universitaria S. Anna, University of Ferrara, Italy

Full Professor of Hematology University of Ferrara, Director of Hematology Section – Azienda Ospedaliero Universitaria Arcispedale S. Anna Ferrara

Work Experience

October 1988- March 1989: Visiting Scientist At Centre For Human Genetics; K.U.L. Leuven, Belgium During Studies For PH.D. In Experimental Hematology, Then Frequent Short Stays Until 1995.

1990: “Appointed as full-time Researcher” at the Section of Hematology, University of Ferrara, with an established role in providing health care in the Hematology Unit of the Azienda Ospedaliero Universitaria in Ferrara –

2001: Associate Professor of Hematology , University of Ferrara

2005: Full Professor of Hematology, University of Ferrara

2006: Director of Hematology Section – S. ANNA University Hospital, Ferrara

2011-2015: Coordinator Ph.D. Programme in Molecular Medicine and Pharmacology, University of Ferrara

2012-2017: Director of the Department of Specialistic Medicine at the University Hospital in Ferrara, Italy

February 2019: Full professor of Hematology University of Ferrara (50% Full Time Equivalent) and University of Parma (50% FTE)

Organisational Skills & Competences

  • Member of the Italian Society of Hematology and of Italian Society of Experimental Hematology
  • Member of Board of the Italian Society of Experimental Hematology from 1997 till 2002
  • President of the Italian Society of Experimental Hematology for biennium 2007-2008
  • President of Interfaculty Specialist Degree Course of Medical-Pharmaceutical Biotechnologies for biennium 2006-2007
  • Coordinator of Ph.D. school of Pharmacology and Molecular Oncology
  • January 2011- December 2015
  • October 2015-October 2019: President of the “College of the full professors of Hematology of the Italian universities”
  • August 2018: President of the Scientific Committee of the GIMEMA foundation
  • May 2021: Chairman of the national working party of the GIMEMA group on ‘chronic lymphocytic leukemia and chronic lymphoproliferative disorders’